Democratizing hedge fund level analysis tools for everyone
| Name | Millennium Pharmacon International Tbk. |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Health Care Research |
| Code | F2 |
| Latest Quarterly | 06-30-25 |
| Name | Latest % | A Month Ago % |
|---|---|---|
| Pharmaniaga International Corporation Sdn. Bhd. | 73.43 | 73.43 |
| Public < 5% | 16.85 | 16.85 |
| PT. Danpac Pharma | 9.72 | 9.72 |
| Source | 2022 | 2021 |
|---|---|---|
| SDPC | F2 | Prescription Medicine |
| SDPC | F2 | Medical Devices |
| SDPC | F2 | Non-prescription Medicine |
| SDPC | F2 | Others |
| SDPC | F2 | Other |
| Region | 2022 | 2021 |
|---|---|---|
| SDPC | F2 | Indonesia |
| SDPC | F2 | Others |
| Valuation | Ratio | Rank |
|---|---|---|
| P/S | 0.05 | # 1 / 15 |
| EV_EBITDA | 12.97 | # 8 / 15 |
| PER | 5.40 | --- / 15 |
| PBV | 0.58 | # 1 / 15 |
| DER | 5.36 | # 13 / 15 |
| Profitability | Ratio | Rank |
|---|---|---|
| NPM % | 0.86199999999999 | # 10 / 15 |
| ROA % | 1.78 | # 10 / 15 |
| ROE % | 10.97999999999999 | # 9 / 15 |
| Year | DPS | Yield [%] |
|---|---|---|
| 2024 | 5.0 | 3.8 |
| 2023 | 4.0 | 2.6 |
| 2022 | 2.0 | 0.6 |
| 2021 | 1.0 | 0.8 |
| 2020 | 2.0 | 2.0 |
| 2019 | 6.0 | 6.4 |
| Timeframe | Performance |
|---|---|
| 1W % | 3.0 |
| 1Mo % | 3.0 |
| 3Mo % | 8.6 |
| 1Yr % | 1.5 |
| Stocks | PER | Market Cap | EV | Revenue | EBITDA | Net Profit |
|---|---|---|---|---|---|---|
| KLBF | 15.76 | 62.26 T | 63.77 T | 34,159 B | 5,862 B | 3,950 B |
| SOHO | 44.61 | 25.89 T | 28.01 T | 10,338 B | 711 B | 581 B |
| SIDO | 14.24 | 17.10 T | 16.78 T | 3,657 B | 1,604 B | 1,201 B |
| TSPC | 8.97 | 12.63 T | 11.54 T | 13,197 B | 1,807 B | 1,404 B |
| PYFA | -13.79 | 5.90 T | 11.63 T | 2,771 B | -27 B | -426 B |
| KAEF | -8.56 | 3.48 T | 14.83 T | 8,673 B | 365 B | -409 B |